Navigation Links
ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments
Date:9/26/2007

The access code for the live call is 89370716. To access the 24-hour audio replay, U.S. and Canadian participants may dial (888) 286-8010; international participants may dial (617) 801-6888. The access code for the replay is 21178468. This conference call will also be webcast live and archived on ISTA's website for 30 days at http://www.istavision.com.

About Bepotastine

Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd., under the brand name TALION. TALION was co-developed by Tanabe Seiyaku and Ube Industries, Ltd., who discovered bepotastine. In 2001, Tanabe Seiyaku granted Senju Pharmaceutical Co., Ltd. exclusive worldwide rights, with the exception of certain Asian countries, to develop, manufacture and market bepotastine for ophthalmic use. ISTA licensed the North American rights to ophthalmic allergy applications of bepotastine from Senju in 2006.

About ISTA

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $3.2 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share. The Company's product development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.

About Tanabe

TANABE SEIYAKU CO., LTD. is one of the leading Japanese pharmaceutical companies that specializes in developing a
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...itis reported at Federation of Clinical Immunology...makes these people susceptible to the disabling in...closed the circle between key genes identified in ... Center for Genomics and Human Genetics at The Fei...
...tle surprises up its sleeves; one of which is a su...g to experts, the spread of dengue, which is trans...c in much of the region, has also accelerated in r... urbanization and travel or migration within the r...
... who was admitted to a hospital in East Delhi afte...aising speculations of a suicide attempt by him, ... a statement to the Delhi Police, Singh said that ...lass window panes broke when he banged his hands o...
...t how the Ice Age in Europe dried up the West Afri...of scientists from the University of California, S...ry of the West African monsoon yet, spanning 155,0...ges. They analysed the amount of barium in plankt...
Other Medicine News:Health News:New Developments in Rheumatoid Arthritis 2Health News:New Developments in Rheumatoid Arthritis 3Health News:Dengue Sweeping Across Southeast Asia 2
(Date:9/3/2008)...s Phase 3 Plans with FDA, PRINCETON, N.J., Sept. ...ced today that it successfully completed two key c... new, innovative low-dose, once-weekly,contracept...rnal product,code AG-200-15. The Phase 2b safety a...point of ovulation suppression, cycle control and ...
(Date:9/3/2008)...trong Evidence Pycnogenol(R) Lowers Joint, Pain, S...lowing Cessation of th... According to the Center for,Disease Control (CDC)...s,is on the rise. A new study published in the Au...nogenol(R), bark extract from the French maritime ...
(Date:9/3/2008)...wswire-FirstCall/ -- A sub-analysis of,the TRITON-...prasugrel,compared with clopidogrel significantly ... (7.4 percent vs. 9.7 percent, p<0.0001), regardle...of an artery-opening,procedure known as percutaneo...d spontaneously during the longer-term maintenance...
(Date:9/2/2008)...-FirstCall/ --, - This Analysis Showed That Multa... 34% in Patients With Atrial Fibrillation or Atria...otic Therapy, The results of a post-hoc analysis ...oday at the clinical trial update session of the E...nich, Germany. Previous results,from the landmark ...
Breaking Medicine Technology:Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 2Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 3Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 6Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Sinexus Welcomes New CEO and Completes Series B 21149 1Sinexus Welcomes New CEO and Completes Series B 21149 2Sinexus Welcomes New CEO and Completes Series B 21149 3Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi Center Radiation Therapy Systems Agreement 21144 1Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi Center Radiation Therapy Systems Agreement 21144 2Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi Center Radiation Therapy Systems Agreement 21144 3Summer is for Sleeping 3F Exhausted Americans Challenged to Sleep in on Longest Day of the Year 21139 1Summer is for Sleeping 3F Exhausted Americans Challenged to Sleep in on Longest Day of the Year 21139 2Summer is for Sleeping 3F Exhausted Americans Challenged to Sleep in on Longest Day of the Year 21139 3Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 1Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 2Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 3Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 4
...zed phase II/III clinical trial,anticipated later ...tCall/ -- Cell,Therapeutics, Inc. (CTI) announced ...nstrate that treatment with pixantrone (BBR,2778) ...ty, while,doxorubicin and mitoxantrone induced sig...cardiac side effects of equiactive doses,of pixant...
...WIRE)--Jun 26, 2007 - Sirtris,Pharmaceuticals, Inc...sed on discovering and developing small molecule d...hat activation of SIRT1, a,member of the sirtuin f...rodegenerative diseases such as Alzheimer,s Diseas...ls. These findings,appear in an article published ...
Other Medicine Technology:Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 2Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 3Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 4Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 5Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 6Resveratrol Studies Suggest Broad Implications for SIRT1 Activation,in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease 2Resveratrol Studies Suggest Broad Implications for SIRT1 Activation,in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease 3
High sensitive, specific one step immunochromatographic assay for human infectious disease
Span Diagnostics Limited
Malaria (P. fal.) Ag Rapid Test
OptiMAL is a malaria test, for diagnosis and therapy control of an infection by Plasmodium species (Malaria).
Medicine Products: